Abstract | BACKGROUND: METHODS: Open multicentre, phase IV study (www.clinicaltrials.govNCT01323959) in which healthy adults, who had received a previous dose of dTpa-IPV, dTpa+IPV or Td-IPV ten years earlier, received a single decennial booster dose of dTpa-IPV ( Boostrix- polio, GlaxoSmithKline Vaccines). Blood samples were collected before and one month after booster vaccination. Antibody concentrations against all vaccine antigens were measured and reactogenicity and safety were assessed. RESULTS: A total of 211 subjects (mean age 50.3 years) received vaccination of whom 201 were included in the according-to-protocol cohort for immunogenicity. Before the decennial dTpa-IPV booster, ≥71.0% subjects were seroprotected/seropositive against all vaccine antigens. One month after the booster dose, all subjects were seroprotected against tetanus and poliovirus types 2 and 3; ≥95.7% subjects were seroprotected against diphtheria and ≥98.3% against poliovirus type 1. Anti- pertussis booster responses for the various antigens were observed in ≥76.5% ( pertussis toxoid; PT), ≥85.1% (filamentous haemagglutinin; FHA) and ≥63.2% ( pertactin; PRN) of subjects. During the 4-day follow-up, the overall incidence of local AEs was 71.6%, 75.0% and 72.2% in dTpa-IPV, dTpa+IPV and Td-IPV groups, respectively. Pain was the most frequent solicited local adverse event (AE; ≥62.7% subjects) and fatigue the most frequent solicited general AE (≥18.5%). No serious AEs were reported during the study. CONCLUSION: A booster dose of dTpa-IPV was immunogenic and well tolerated in adults who had received a booster dose of either dTpa-IPV, dTpa+IPV or Td-IPV, ten years previously and supports the repeated administration of dTpa-IPV.
|
Authors | Martina Kovac, Niraj Rathi, Sherine Kuriyakose, Karin Hardt, Tino F Schwarz |
Journal | Vaccine
(Vaccine)
Vol. 33
Issue 22
Pg. 2594-601
(May 21 2015)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 25882172
(Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- Antibodies, Bacterial
- Antibodies, Viral
- Boostrix
- Diphtheria Toxin
- Diphtheria-Tetanus-Pertussis Vaccine
- Diphtheria-Tetanus-acellular Pertussis Vaccines
- Poliovirus Vaccine, Inactivated
- Tetanus Toxin
- Vaccines, Combined
|
Topics |
- Adult
- Antibodies, Bacterial
(blood)
- Antibodies, Viral
(blood)
- Diphtheria Toxin
(immunology)
- Diphtheria-Tetanus-Pertussis Vaccine
(administration & dosage, adverse effects, immunology)
- Diphtheria-Tetanus-acellular Pertussis Vaccines
(administration & dosage, adverse effects, immunology)
- Female
- Follow-Up Studies
- France
- Germany
- Healthy Volunteers
- Humans
- Immunization, Secondary
- Injections, Intramuscular
- Male
- Middle Aged
- Poliovirus
(immunology)
- Poliovirus Vaccine, Inactivated
(administration & dosage, adverse effects, immunology)
- Tetanus Toxin
- Time Factors
- Vaccines, Combined
(administration & dosage, adverse effects, immunology)
|